Emergent BioSolutions (NYSE:EBS) Raised to “Buy” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Friday, January 10th. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

EBS opened at $9.46 on Tuesday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The business’s 50 day moving average is $9.37 and its 200-day moving average is $9.18. The stock has a market cap of $512.58 million, a PE ratio of -2.31 and a beta of 1.60. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10.

Institutional Trading of Emergent BioSolutions

A number of hedge funds have recently made changes to their positions in the stock. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions in the third quarter worth $96,000. FORA Capital LLC acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth $103,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at $93,000. Morse Asset Management Inc bought a new stake in Emergent BioSolutions in the second quarter worth $97,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Emergent BioSolutions during the third quarter worth $141,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.